Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 12:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ropinirole (Requip) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole

NCT00422994
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
ropinirole dosing for up to 28 days
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 25, 2026, 12:34 AM EDT
Completed Phase 4 Interventional

SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole

NCT00344994
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
pramipexole
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated May 13, 2011 · Synced Oct 25, 2026, 12:34 AM EDT
Completed Phase 3 Interventional

Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome

NCT00355641
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Ropinirole Extended Release (XR)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
59
States / cities
Alabaster, Alabama • Jasper, Alabama • Mesa, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 25, 2026, 12:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Ropinirole 0.25 mg Tablets Under Fasting Conditions

NCT00829504
View directory record Official record
Conditions
Healthy
Interventions
Ropinirole HCl 0.25 mg Tablets, Requip® 0.25 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2009 · Synced Oct 25, 2026, 12:34 AM EDT
Completed Phase 4 Interventional Results available

A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease

NCT01494532
View directory record Official record
Conditions
Parkinson Disease
Interventions
ropinirole/L-dopa, placebo/L-dopa
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
Fountain Valley, California • Pasadena, California • Reseda, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 25, 2026, 12:34 AM EDT
Completed Phase 3 Interventional

MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist

NCT00605683
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
Safinamide (as add-on therapy)
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
30 Years to 80 Years
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Oxnard, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Oct 25, 2026, 12:34 AM EDT
Completed Phase 1 Interventional

Ropinirole Tablets In Young Patients With Restless Legs Syndrome

NCT00140712
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Ropinirole Immediate Release
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Macon, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 25, 2026, 12:34 AM EDT
Completed Phase 3 Interventional Results available

Impact of Switching to Continuous Release Dopamine Agonists

NCT00465452
View directory record Official record
Conditions
Parkinson Disease
Interventions
Continuous Release Dopamine Agonists
Drug
Lead sponsor
University of Toledo
Other
Eligibility
55 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 25, 2026, 12:34 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Gait Analysis in Neurological Disease

NCT02994719
View directory record Official record
Conditions
Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Gait, Frontal, Huntington Disease, Ataxia, Spinocerebellar
Interventions
Anti-Parkinson medication, Deep Brain Stimulation
Drug · Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 25, 2026, 12:34 AM EDT
Completed Phase 4 Interventional Results available

Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis

NCT03176966
View directory record Official record
Conditions
Muscle Cramp, Cirrhosis
Interventions
Vitamin E, Ropinirole, Muscle cramp survey
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Oct 25, 2026, 12:34 AM EDT
Completed Phase 4 Interventional

Ropinirole in the Treatment of Bipolar Depression

NCT00314821
View directory record Official record
Conditions
Bipolar Disorder
Interventions
ropinirole
Drug
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Atlanta, Georgia • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 25, 2026, 12:34 AM EDT
Completed Phase 3 Interventional

Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome

NCT00197080
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Ropinirole Extended Release (XR)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
60
States / cities
Alabaster, Alabama • Jasper, Alabama • Mesa, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 25, 2026, 12:34 AM EDT
Withdrawn Phase 4 Interventional

Butrans for Treatment of Restless Legs Syndrome

NCT02138357
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
buprenorphine transdermal delivery system (BTDS), Placebo for BTDS patch
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 25, 2026, 12:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole

NCT03038308
View directory record Official record
Conditions
Hyperprolactinemia, Prolactinoma
Interventions
Ropinirole
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 25, 2026, 12:34 AM EDT
Not listed Phase 3 Interventional

Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease

NCT00260793
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Ropinirole Hydrochloride
Drug
Lead sponsor
Agarwal, Pinky, M.D.
Individual
Eligibility
25 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 3, 2006 · Synced Oct 25, 2026, 12:34 AM EDT
Completed Phase 4 Interventional Results available

A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease

NCT01485172
View directory record Official record
Conditions
Parkinson Disease
Interventions
ropinirole monotherapy, placebo monotherapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
11
States / cities
Fountain Valley, California • Pasadena, California • Reseda, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 25, 2026, 12:34 AM EDT
Completed Phase 4 Interventional Results available

Naltrexone for Impulse Control Disorders in Parkinson's Disease

NCT01052831
View directory record Official record
Conditions
Impulse Control Disorder, Parkinson Disease
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Oct 25, 2026, 12:34 AM EDT
Completed Phase 3 Interventional Results available

Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)

NCT00256854
View directory record Official record
Conditions
Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Interventions
Ropinirole IR 1 mg, Ropinirole IR 2 mg, Ropinirole IR 1 mg Placebo, Ropinirole IR 2 mg Placebo, Ropinirole CR 2 mg, Ropinirole CR 3 mg, Ropinirole CR 2 mg Placebo, Ropinirole CR 3 mg Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
30
States / cities
Laguna Hills, California • Oxnard, California • Pasadena, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 25, 2026, 12:34 AM EDT
Completed Phase 3 Interventional

Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa

NCT00381472
View directory record Official record
Conditions
Parkinson Disease
Interventions
Ropinirole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years and older
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
28
States / cities
Birmingham, Alabama • Northridge, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 25, 2026, 12:34 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Ropinirole on Spinal Cord Reflexes and Restless Legs Syndrome

NCT00051961
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 12:34 AM EDT
Completed Phase 4 Interventional Results available

A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease

NCT01711866
View directory record Official record
Conditions
Advanced Idiopathic Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
30 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Anniston, Alabama • Atlantis, Florida • Miami Springs, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Oct 25, 2026, 12:34 AM EDT
Completed Phase 3 Interventional Results available

Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164

NCT00650104
View directory record Official record
Conditions
Parkinson Disease
Interventions
Ropinirole XL (formerly CR)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • Oxnard, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Oct 25, 2026, 12:34 AM EDT
Completed Phase 3 Interventional Results available

Pramipexole Conversion to Ropinirole Controlled Release (CR)

NCT00275275
View directory record Official record
Conditions
Parkinson Disease
Interventions
Requip PR, Mirapex
Drug
Lead sponsor
Rajesh Pahwa, MD
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2012 · Synced Oct 25, 2026, 12:34 AM EDT
Completed Phase 3 Interventional

Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.

NCT00036218
View directory record Official record
Conditions
Parkinson Disease
Interventions
sumanirole, ropinirole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
93
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Carmichael, California + 81 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2006 · Synced Oct 25, 2026, 12:34 AM EDT